Member Info for chester18

As the Covidity trial continues towards a full phase1 data readout ( May 2022 ) the current Coronavirus pandemic will have began to ebb away, especially as the weather warms. The main success of Covidity will be the clarity of targeting ( non toxic ) and the strength of the 'T' Cell immune response.

If we see impressive results against the Coronavirus Nucleus then the Immunobody Platform will be able to target any Virus of choice. In that scenario it becomes an extremely important / valuable asset going forwards.

My point being that the future potential of Covidity is not dependant on the state of the pandemic when the data is reported it is the strength of the immune responses to the chosen targets.

Chester.

Hi violindog

Somewhere in the trial docs it did say that blood samples would be taken and anylised and if I remember correctly it was some 6 week after the 2nd dose. So if everything has gone smoothly Scancell will have completed and partially completed blood works from the first 16 ish volunteers.

This is the data we are hoping to be RNS'd by Mid Feb. It is also very possible that they have enough of that data to let us know this week.

What we might hear is, Covidity Well Tolerated, Both Antibodies and 'T' Cells activated against both the Spike and the Nucleocapsid targeted proteins / epitopes.

Hope that helps...

Chester.

Hi C11, to try and answer part of your question from what we do know.

At the time of the AGM we were told that 16 volunteers had been enrolled so very possible that number had also given their first 'needle free' jab.

The trial had started slowly to ensure the safety of the drug / dose, but by the time of the AGM (which was at the end of November) the enrolment was expected to move forward at a speed of 6 new volunteers per week.

The trial is set for 40 volunteers so 24 still had to be enrolled.
24 divided by 6 = 4 weeks.

Allowing for some slowdown for Christmas and New year if the clinic has moved at that pace it is very likely that all 40 have now had their first dose and the original 16 from the end of November their 2nd.

I know its not a guarantee but very possible that these numbers are where we are at the present time.

Chester.

Hi KonarA

Just to add to that, our CEO, Prof. Durrant did say there could be a partial read out of the safety aspect of the trial, late January / early February. So Covidity news is possible next week but we may need to wait until mid Feb.

It will depend on when the necessary data is in their hands.

Chester.

It would seem that most pundits are calling the current wave of Covid-19 ( Omicron ) as 'Over and Done'.

Just as Scancell are about reveal if the Covidity Vaccine has the potential to offer greater protection against all Covid-19 variants. Does this mean we've missed the boat ?

The correct answer is : No................

Without the roll out of the last booster in the UK the number of hospitalisations could have been double or treble what we saw. The current vaccines and their boosters against Omicron are not lasting more that six months, so what happens when the vaccine's antibodies offer little or no protection and a new wave or new mutation rears its ugly head.

" Booster number 4 Please " and then possibly Booster number 5 until a more powerful 2nd Generation Vaccine is 'Phase 3' approved. A positive Phase1 Report from Covidity is exactly what the world needs to hear, only when we have a long lasting Universal Covid Vaccine will our pre-March 2020 lives have a chance of returning.

Chester.

The Interim report will throw some light on all of our platforms. Of course there will be the amount spent ( losses ) but that's what Redmile's investment was for, spending. The quicker we move through the early stages the quicker we will see the science actually inside patients and hopefully making a significant difference to outcomes. That includes MODI2, SCIB2, AvidiMab and GlycanMabs.

Interims always look forward as well as backwards, the main thrust about the future being what the company hopes to achieve in the next 6 months. If the current wave of the pandemic wanes we know the MODI1 and SCIB1 trials will progress quickly. That will be a great day when the MODI1 trial actually begins.

Prof. Durrant is always upbeat and enthusiastic about the prospects of Scancells science so if there is a Proactive Investors interview later on Wednesday that again could contain a few more snippets of info... hope so.

We've waited a long time to see the Cancer Vaccine trials start in earnest.
Good luck to all SCLPers.

Chester.

Hi Doublehun

£150m for the 5% still only takes us back to a value of £900m ( £150m in cash + the 25% worth £750m ) and an SP 22p, so you must have a tonne of shares.

Chester.

Chester.

If the 5% is a low ball valuation it would mean that the 'Competent Person' has ignored the last twelve months of Infill and Expansion drilling which they are not allowed to do. Also, will a low valuation not allow a predator to strike and put a bid in for the whole of Greatland Gold ??

Based on all the indications we have as to the size of the mineralization, the mineable % of the ore body and the economics debated on here I would say £150m minimum upto a potential high of £215m.

Chester.

Hiya Ruck

The SP will bounce around as people buy and sell for all manner of reasons and speculations. As I have stated many times, I am invested in Scancell because of Moditope and Immunobody. The Covidity platform has the potential to transform Scancell, given that it is as successful as we hope it will be, it will also validate the Immunobody Platform and show us that AvidiMab is going to be a very important and valuable platform to other Pharma companies.

A proven AvidiMab will not only increase the potency of a huge range of Antibody Drugs but will allow those Pharma companies to increase the exclusivity shelf life to boot.

Interims next week with as much positive spin as possible please, followed in a couple of weeks the Covidity Update.

Cannot Wait,

Chester.

Why is it that every time we try to discuss the potential of Scancell or the science that's about to be announced we have descend into this petty squabble about the daily movements of the SP.

So unnecessary ...................

Chester.

Hi Coolfree

My point is that the SP has been moving around in a vacuum but more tangible and ( if I may say ) valuable news is now very close. Next weeks drill report will be as previous, more outstanding results, probably increasing the mineralization at depth and increasing the number of recoverable ounces. It might even point towards the other Havieron targets having commercial grades. Add to that, the value put on the FMV 5% when it comes could lift the SP by 5p on the day.
I'm not expecting fireworks but the Scallywag results could come back with even more positive results allowing GGP to hone in on another potential ore body.

So are we finally at the point where all these combined news items will see the back of this 14p nadir.

Chester.

Hi Mcilroy987

Newcrest Key dates : ( from their webpage )

December 2021 Quarterly Results. 28 January 2022. ...
Half Year Results. 17 February 2022. ...
March 2022 Quarterly Results. 28 April 2022. ...
June 2022 Quarterly Results. 21 July 2022. ...
Full Year Results. 19 August 2022. ...
September 2022 Quarterly Results. 27 October 2022.

ATB

Chester.

Good post krafty

When we do hear the update on Covidity if Scancell can say 'Well Tolerated', 'Evidence of Spike Protein Antibodies' and 'Evidence of newly generated 'T' Cells against both the Spike and Nucleocapsid Proteins' then the government will be lauding Covidity as the best thing since sliced bread. Plus claiming that it was the British Government that backed the science and hence the success.

In brief, that's all we need, a good positive update that Covidity is doing what it says on the tin.

Chester.

With the Newcrest Quarterly next Thursday, the 5% Fair Market Value being debated, the remaining outstanding exploration drill cores due any time and our close neighbours getting very excited about their own prospects, is this the last chance saloon for this lowball 14p a share ??

Chester.

Thank you Bermudashorts for a very timely reminder of the huge importance of our Immunobody Vaccine enhanced with AvidiMab. To hear that Scancell are seeing Covidity promoted Antibodies and CD4 / CD8 'T' Cell will be such an advance over the current re-formulated Spike antibody vaccines.

I am looking forward to the Interim report on the 26th but I am well aware that we may not hear news from the Covidity Trial until a few weeks later.

Just to add, the MODI1 Trial could actually start early February as the NHS finally begins to see Omicrom hospitalization numbers reduce to a manageable size, that should also give the SCIB1 trial the opportunity to enrol further patients.

Chester.

Understandably we are all focused on Covidity, nice touch if JVT did have a role to play. However 2022 has such a lot more in store for Scancell.

MODI1 Trial - start and read outs.
SCIB1 / Keytruda Trial - one patient already dosed with more to add ASAP
AvidiMab - Collaborations to develop towards deals.
SCIB2 - Progression at the new labs in Oxford.
MODI2 - again to be progressed at Oxford.
Glycan Mabs.
TCR - Once MODI1 is fully in the clinical.

Chester.

Could this agreement with Fosun Pharma be that Rene are clearing the decks with regards to any residual CTX commitments. Still retain royalties if the platform is fully developed by Fosun but now all the major responsibilities lie with them.

An extra £320k in the bank and concentrate on RP and Exosomes.

Seems to be a sensible way forward.

Chester.

Interim reports are always interesting as they confirm the path travelled but also look to the second half of the year. Also Prof. Durrant's first interim as CEO and we may see a Proactive Investors interview as well.

The Covidity update as stated will be end Jan / early Feb. If it is close to the 26th Jan then we can presume there is good enough data to make an earlier announcement, which also infers that bigger wheels are in motion.

Very exciting times as we are now so close to the tipping point. Also just as important we will be updated on both the SCIB1 enrolment progress and how close we are to seeing the first patient dosed with MODI1.

These are all huge steps forward.

Chester.

From the RNS released Tue, 22nd Jun 2021 07:00 RNS Number : 6170C
The Initial target SN14 has now been superseded by SN15 and due to further mutations candidate SN17 is added.

The Company is pleased to note the publication of preclinical data on its two lead bivalent vaccine candidates SN15 (also known as SCOV1) and SN17 (also known as SCOV2). These next generation COVID-19 vaccines could offer improved protection against new SARS-Cov-2 variants of concern (VoC) due to the inclusion of the highly conserved nucleocapsid N antigen in addition to the more variable spike (S) protein. Based on the potent immune responses generated in these preclinical studies, Scancell plans to test the safety and immunogenicity of SCOV1 and SCOV2 in a Phase 1 clinical trial.

SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology and have a dual mechanism of action to induce high avidity T-cell immune responses against both the N and S viral antigens. Targeting the receptor-binding domain (RBD) of the S antigen, the vaccines also elicit high titre virus-neutralising antibodies (VNAbs) that can cross-react against a range of variants of concern, including the Beta variant first identified in South Africa.

The paper shows that SN15 elicits strong pro-inflammatory T-cell responses to both the N and S proteins, with these responses being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc utilising Scancell's AvidiMab™ technology. The SN15 vaccine also stimulates high titre neutralising antibody (VNAbs) responses to the receptor binding domain (RBD) of the S protein and shows cross reactivity with S proteins from the emerging variants Alpha (B.1.1.7; Kent) and Beta (B.1.351; South African).

The Company believes this DNA platform can be easily adapted to target variant RBD and N proteins and demonstrates that SN17, encoding the Beta RBD sequence, stimulates cross-reactive antibody mediated and T-cell immunity. The paper supports the translation of this DNA vaccine platform into the clinic, thereby offering a particular advantage for targeting emerging SARS-CoV-2 variants.

Prof Lindy Durrant, Founder and Chief Scientific Officer, Scancell, commented: "We believe that the combination of cross-reactive VNAbs with durable memory responses against the conserved N protein may confer an added advantage by eliciting potent T cells that can destroy cells infected with any of the variant viruses, providing an extra layer of protective surveillance."

Announcement about the 'Initial target' for Covidity. ( SN14 ) as the variants emerged we saw SN15 added

RNS Number : 0847J Fri, 18th Dec 2020 07:00
Scancell Holdings plc

Scancell announces selection of COVID-19 vaccine candidate, SN14
SN14 offers several potential advantages over currently approved and late-stage COVID-19 vaccines
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies is pleased to announce that they have selected their COVID-19 vaccine candidate, SN14, for further development and clinical trials. SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain (RBD) of the spike (S) protein, and is based on a modification of Scancell's ImmunoBody® DNA vaccine technology.

Fifteen vaccine candidates containing different S and N components combined with a variety of targeting technologies were evaluated for the best T cell and antibody responses. SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins. SN14 also incorporates Scancell's AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.
SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:
· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.
· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.
· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.
· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using relatively simple processes.
As reported in October 2020, Scancell entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of SN14 with the goal of starting a Phase 1 COVIDITY clinical trial as soon as possible during 2021. The project is funded by an Innovate UK grant awarded to a consortium between Scancell, the University of Nottingham and Trent University.

Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:
"We are very excited about our SN14 second generation COVID-19 vaccine which could have significant advantages over first generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long term protection".